ProCE Banner Activity

Phase II ATEMPT: Analysis of Adjuvant Trastuzumab Emtansine (T-DM1) vs Paclitaxel Plus Trastuzumab in Patients With Stage I HER2-Positive Breast Cancer

Slideset Download
Conference Coverage
Phase II ATEMPT trial shows very few recurrences with adjuvant T-DM1 but similar rates of AEs as TH at 3-year follow-up in patients with stage I HER2-positive breast cancer.

Released: December 19, 2019

Expiration: December 17, 2020

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen